BFM
TVTX icon

Boothbay Fund Management’s Travere Therapeutics TVTX Stock Holding History

Boothbay Fund Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-81,825
Closed -$2.66M – 2377
2025
Q3 		$1.96M Buy
+81,825
New +$1.54M 0.03% 575
2015
Q4 		– Sell
-18,185
Closed -$368K – 656
2015
Q3 		$368K Buy
+18,185
New +$539K 0.17% 134

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's TVTX Position: Q4 2025 in Review

Boothbay Fund Management sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 81,825 shares — an estimated $2.66M sold.

Boothbay Fund Management first reported a position in TVTX in Q3 2015 and held it in 2 quarters. The position peaked at $1.96M in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Boothbay Fund Management reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 81,825 Travere Therapeutics shares in Q4 2025, an estimated $2.66M.
  • Boothbay Fund Management first reported a position in Travere Therapeutics in Q3 2015 and held it in 2 quarters.
  • Boothbay Fund Management's Travere Therapeutics position peaked at $1.96M in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.